Corgi Data & Surveillance ETF (EYES)
BATS:EYES
Want to see EYES full AI Analyst Report?
EYES Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
EYES FAQ
What was Corgi Data & Surveillance ETF’s price range in the past 12 months?
Currently, no data Available
What is Corgi Data & Surveillance ETF’s market cap?
Currently, no data Available
When is Corgi Data & Surveillance ETF’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Corgi Data & Surveillance ETF’s earnings last quarter?
Currently, no data Available
Is Corgi Data & Surveillance ETF overvalued?
According to Wall Street analysts Corgi Data & Surveillance ETF’s price is currently Undervalued.
Does Corgi Data & Surveillance ETF pay dividends?
Corgi Data & Surveillance ETF does not currently pay dividends.
What is Corgi Data & Surveillance ETF’s EPS estimate?
Corgi Data & Surveillance ETF’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Corgi Data & Surveillance ETF have?
Currently, no data Available
What happened to Corgi Data & Surveillance ETF’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Corgi Data & Surveillance ETF?
Currently, no hedge funds are holding shares in EYES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Corgi Data & Surveillance ETF
As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.